医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SEOUL, South Korea

Hanmi Pharmaceutical co., Ltd. (KSE:128940) will present the results of the phase I/II domestic clinical trial of HM61713 in patients with EGFR mutation positive non-small cell lung cancer at the 51^st American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2015, in Chicago, USA.

During the conference, Hanmi Pharmaceutical will participate in a session on Lung Cancer-Non-Small Cell Metastatic, and will give a poster presentation on the results of the phase I/II domestic clinical trial with 195 patients of EGFR mutation positive non-small cell lung cancer administered with HM61713.

HM61713 selectively inhibits the mutation of signal delivery substance EGFR involved in the growth of cancer cells, and is evaluated as the third-generation EGFR tyrosine kinase inhibitor (TKI) which overcomes resistance and side effects after administration with previous EGFR TKIs Iressa^® and Tarceva^®.

Presentation Schedule (local time)

HM61713 (HM-EMSI-101)
Updated safety and efficacy results from I/II study of HM61713 in patients with EGFR mutation positive non-small cell lung cancer who failed previous EGFR-tyrosine kinase inhibitor, Poster Session, at 08:00 on Jun 1 (Mon).

Hanmi Pharmaceutical co., Ltd.
Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting biologics including weekly Insulin, weekly to monthly GLP-1, and their combination for diabetes and obesity (collectively referred as Quantum Project), the novel targeted anti-cancer drugs with improved tolerance and safety profile and fixed-dose combination drugs. For more detail about the company, visit http://www.hanmipharm.com .

View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005595/en/